Search Results - "HÄBE, Sonja"

TP53 Mutation and Survival in Chronic Lymphocytic Leukemia by ZENZ, Thorsten, EICHHORST, Barbara, HENSEL, Manfred, HALLEK, Michael, DÖHNER, Hartmut, STILGENBAUER, Stephan, BUSCH, Raymonde, DENZEL, Tina, HÄBE, Sonja, WINKLER, Dirk, BÜHLER, Andreas, EDELMANN, Jennifer, BERGMANN, Manuela, HOPFINGER, Georg

“…The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to…”
Get full text

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial by Zenz, Thorsten, Häbe, Sonja, Denzel, Tina, Mohr, Julia, Winkler, Dirk, Bühler, Andreas, Sarno, Antonio, Groner, Silja, Mertens, Daniel, Busch, Raymonde, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan

“…The prognosis of fludarabine (F)–refractory chronic lymphocytic leukemia (CLL) is very poor, and underlying mechanisms are only partly understood. To assess…”
Get full text

The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia by Zenz, Thorsten, Häbe, Sonja, Benner, Axel, Kienle, Dirk, Döhner, Hartmut, Stilgenbauer, Stephan

Get full text

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution by Zenz, Thorsten, Sarno, Antonio, Häbe, Sonja, Denzel, Tina, Mohr, Julia, Vollmer, Dominik, Heuberger, Maria, Winkler, Dirk, Kienle, Dirk, Bühler, Andreas, Truong, Sim, Patten, Nancy, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan

“…The prognosis of CLL with 17p deletion is very poor. While it is generally accepted that inactivation of p53 (by mutation) underlies refractoriness of CLL with…”
Get full text

p53 Inactivation in CLL: Pattern of 110 TP53 Mutations by Zenz, Thorsten, Trbusek, Martin, Smardova, Jana, Häbe, Sonja, Denzel, Tina, Malcikova, Jitka, Doubek, Michael, Schwarz, Jiri, Dohner, Hartmut, Stilgenbauer, Stephan

“…TP53 mutations have been shown to occur in 5–15% of CLL patients and are associated with a poor response to treatment. Because previous studies have examined…”
Get full text

TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations by Zenz, Thorsten, Smadova, Jana, Vollmer, Dominik, Trbusek, Martin, Benner, Axel, Häbe, Sonja, Denzel, Tina, Malcikova, Jitka, Truong, Sim, Patten, Nancy, Oscier, David, Ibbotson, Rachel, Gardiner, Anne, Tracy, Ian, Lin, Ke, Pettitt, Andrew, Popsilova, Sarka, Mayer, Jiri, Döhner, Hartmut, Stilgenbauer, Stephan

“…TP53 mutations have been shown to occur in 5–40% of CLL patients depending on the clinical background (early stage/refractory disease). They are associated…”
Get full text

Influence of MDM2 Single Nucleotide Polymorphism SNP309 on Disease Onset and Course in CLL by Zenz, Thorsten, Häbe, Sonja, Bühler, Andreas, Kröber, Alexander, Denzel, Tina, Döhner, Hartmut, Stilgenbauer, Stephan

“…Background: A SNP in the MDM2 promotor region (SNP309) has been shown to directly influence MDM2 transcript and protein levels with the subsequent attenuation…”
Get full text

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up by Zenz, Thorsten, Kröber, Alexander, Scherer, Katrin, Häbe, Sonja, Bühler, Andreas, Benner, Axel, Denzel, Tina, Winkler, Dirk, Edelmann, Jennifer, Schwänen, Carsten, Döhner, Hartmut, Stilgenbauer, Stephan

“…The exact prognostic role of TP53 mutations (without 17p deletion) and any impact of the deletion without TP53 mutation in CLL are unclear. We studied 126…”
Get full text